Panel Testing Part 2: Actionable Data…again

By: David Shifrin, PhD Science Writer, Filament Life Science Communications Continuing on from the previous post broadly describing the issues around genetic panel testing, this post will go into a bit more detail regarding panel tests and the ever-present issue of actionable data and variants of unknown significance. Researchers and clinicians are pressing forward in determining… Read More Panel Testing Part 2: Actionable Data…again

Panel Testing Part 1: The genetics arm race leads to clinical questions

By: David Shifrin, PhD Science Writer, Filament Life Science Communications Bundling. It’s done in practically every industry, from adding optional features on a new car, to internet and phone service, to academic journal subscriptions. Medicine is no exception. These days, bundling is common in the world of genetic testing. The use of panel tests has increased… Read More Panel Testing Part 1: The genetics arm race leads to clinical questions